Yinghe Brain Science develops a new generation of neuromodulation and brain-computer interface technology and products based on clinical needs.
Recently, Shenzhen Yinghe Brain Science Co., Ltd. (hereinafter referred to as “Yinghe Brain Science”) completed an angel round of financing exceeding 100 million yuan. This round of financing is jointly led by Shenzhen Qianhai Bangqin Investment Co., Ltd. (hereinafter referred to as “Bangqin Capital”) and Eli Lilly Asia Fund (hereinafter referred to as “LAV”). The listed company Shenzhen New Industry Biomedical Engineering Co., Ltd. (hereinafter referred to as “New Industry Biology”), Xijiao 1896 Science and Technology Innovation Fund and a number of institutions followed suit, and the original shareholders of Yingmai Medical continued to increase their holdings. Shenxue Capital acted as the company’s financial advisor in this financing transaction.
Yinghe Brain Science is based in China and faces the world. It develops a new generation of neuromodulation and brain-computer interface technologies and products based on clinical needs. Many products under research are benchmarked against global cutting-edge innovative technologies. Up to now, the R&D team has made breakthroughs in the fields of independent system design, electrode design, chip design, signal acquisition and decoding, algorithm development, MRI compatibility and other technologies, and established a general-purpose neuromodulation platform. Several products under research are about to enter animal experiments and clinical trials.
Dr. Zhao Ruilin, CEO of Yinghe Brain Science, graduated from the junior class of Xi’an Jiaotong University, received a master’s degree in electrical engineering and computer science from MIT in the direction of artificial intelligence, and a PhD in biomedical engineering and medical physics jointly trained by Harvard-MIT. He once specialized in brain neuroscience field of research. The company’s CTO, Dr. Min Xiaoyi, graduated from Sichuan University and holds a doctorate from Michigan State University. He has more than 30 years of experience in research and development of neuromodulation and cardiac rhythm management products in the US headquarters of Medtronic and Abbott, and has more than 160 patents. The company’s core R&D team has more than 30 people. It is an interdisciplinary team covering machinery, electronics, software, chips, systems, scientists, etc. The core technicians have rich experience and technical research capabilities in the field of active medical devices.
Dr. Zhao Ruilin, CEO of Yinghe Brain Science, said: “I am very grateful to the investors for the trust and support of Yinghe Brain Science. In recent years, as China, the United States, Europe, Japan and other countries have successively launched large-scale brain science projects, the development of brain science Entering the golden age, scientists and entrepreneurs around the world are exploring in this field. Yinghe Brain Science is committed to breaking through the neck-blocking technology in the field of brain science by building neural signal sensing, sensing, computing, stimulation and other technologies, and promoting brain The localization of scientific and cutting-edge technology serves the vast number of clinical patients in my country and overseas with high-quality “intelligent manufacturing in China”. This round of financing will further promote the research and development and clinical trials of the company’s core products. In the future, Yinghe Brain Science will also continue to increase Large independent research and development and technology investment will accelerate the application of innovative brain science medical devices to benefit patients around the world.”
Dr. Liu Mingyu, general manager of Bangqin Capital, said: “Brain science and brain-inspired intelligence are an important level in the key development direction of Shenzhen’s ’20+8′ industry, and they are also areas that Bangqin focuses on, especially brain diseases and brain rehabilitation. In this subdivision direction, the clinical effectiveness and accessibility are relatively high. In recent years, the development of new technologies and new materials has driven the expansion of clinical applications in these two directions. We attach great importance to the application and brain science team in the field of neuromodulation With a solid theoretical foundation and rich practical experience, I also believe that the strong industrial chain and talent chain in the Greater Bay Area of Shenzhen and the top business environment in Pingshan District will give infinite support to enterprises.”
Editor in charge: Wei Zirong
media reports
Entrepreneurship State Sina Technology Investment Circle
related events
- Yinghe Brain Science completed an angel round of financing exceeding 100 million yuan2023-01-28
- NeuroEchos, an innovative brain science and brain-computer interface company, received 100 million yuan in financing2022-02-28
- Jingyu Medical completed the D+ round of financing of 300 million yuan, and Sequoia China and Hillhouse Venture Capital jointly led the investment2022-02-16
- “Minimally Invasive Brain Science” received a strategic investment of US$150 million, focusing on the treatment of cerebrovascular diseases2021-11-12
- TAL established a brain science laboratory and will establish an overseas R&D center this year2018-01-25
This article is transferred from: https://readhub.cn/topic/8mWbwga0shE
This site is only for collection, and the copyright belongs to the original author.